Report: VLST slashes workforce in shift to cancer drug research

Xconomy is reporting today that VLST is laying off two thirds of its staff in a cost-cutting move. CEO Martin Simonetti says that he's scaling down from 17 staffers to a virtual staff of 5 as funds are shifted to the development of a cancer drug recently in-licensed from Pfizer ($PFE). "We have very limited resources, and we had to make these extremely difficult decisions," he tells Xconomy. Story


BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.